Viralgen specializes in the production of AAV gene therapy vectors using our proprietary suspension, triple transfection Pro10™ platform. Pro10™ is a unique high yield universal system that can produce all serotypes and chimeric forms of rAAV. Our process utilizes a scalable upstream and robust purification process, coupled with full support for fill and finish, QC, and regulatory support from preclinical to commercial requirements.
2L: feasibility and manufacturability assessment.
50L: non-GMP material for Toxicology/biodistribution studies, reference material or stability studies.
250L/500L: 4 cGMP suites using single-use stirred-tank bioreactors.
Up to 2000L: 9 suites for late phase and commercial manufacturing.